Portal de Periódicos da CAPES

Infliximab and nephrotic syndrome

2005; Oxford University Press; Volume: 20; Issue: 12 Linguagem: Inglês

10.1093/ndt/gfi180

1460-2385

George Chin, Grant Luxton, Jennet Harvey,

Inflammatory Bowel Disease

Infliximab is a chimeric tumor necrosis factor-alpha (TNF-α) monoclonal antibody, which has been used extensively in patients with rheumatoid arthritis and inflammatory bowel disease. It also appears to be effective in other conditions such as psoriasis and ankylosing spondylitis. The major side effect of infliximab is infection. Renal complications are uncommon and not well recognized. This report describes a probable case of infliximab-induced membranous nephropathy.